2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. c-Met/HGFR

c-Met/HGFR

c-Met/HGFR

Related Products

PDF 1.01 MB

c-Met (hepatocyte growth factor receptor, HGFR) is a protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. c-Met is a membrane receptor that is essential for embryonic development and wound healing. Hepatocyte growth factor (HGF) is the only known ligand of the c-Met receptor. c-Met is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymalorigin. Upon HGF stimulation, c-Met induces several biological responses that collectively give rise to a program known as invasive growth.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-45124
    3-Fluoro-desmethyl-cabozantinib
    3-Fluoro-desmethyl-cabozantinib is an BCL6 ligand that can be used in the synthesis of PROTACs, such as SJF-8240 (HY-123961).
    3-Fluoro-desmethyl-cabozantinib
  • HY-147695
    c-Met-IN-12
    		Inhibitor
    c-Met-IN-12 (compound 4r) is an orally active, potent and selective type II c-Met kinase inhibitor, with an IC50 of 10.6 nM. c-Met-IN-12 displays high inhibitory effects (inhibition rate > 80% in 1 μM) against AXL, Mer and TYRO3 kinases. c-Met-IN-12 can be used a scaffold for further kinase selectivity enhancement. c-Met-IN-12 shows antitumor efficacy.
    c-Met-IN-12
  • HY-150582
    c-Met-IN-14
    		Inhibitor
    c-Met-IN-14 (compound 26af) is a selective inhibitor of c-Met kinase from N-sulfonylamidine-based derivatives, with an IC50 value of 2.89 nM. c-Met-IN-14 shows anticancer activity by blocking phosphorylation of c-Met, and arrests cell cycle at G2/M phase. c-Met-IN-14 induces apoptosis of A549 cells in a dose-dependent manner.
    c-Met-IN-14
  • HY-175333
    c-Met ligand-Linker Conjugate 1
    		Inhibitor
    c-Met ligand-Linker Conjugate 1 is an Target Protein Ligand-Linker Conjugate that incorporates a ligand for c-Met (HY-W425461) and a PROTAC linker (HY-151862), which recruits E3 ligases. c-Met ligand-Linker Conjugate 1 can be used for synthesis of PROTAC c-Met degrader-5 (HY-175320).
    c-Met ligand-Linker Conjugate 1
  • HY-170954
    C-Met/Axl-IN-1
    		Inhibitor
    C-Met/Axl-IN-1 (Compound 22a) is an orally active and selective type II c-Met/Axl inhibitor with IC50 values of 1 nM and 10 nM, respectively. C-Met/Axl-IN-1 can inhibit proliferation, induce cell cycle arrest and apoptosis of tumor cells. C-Met/Axl-IN-1 has strong anti-tumor activity.
    C-Met/Axl-IN-1
  • HY-149511
    MET/PDGFRA-IN-2
    		Inhibitor
    MET/PDGFRA-IN-2 (compound 8h) is a MET and PDGFRA protein inhibitor. MET/PDGFRA-IN-2 induces cell apoptosis. MET/PDGFRA-IN-2 inhibits proliferation of MET-positive cells (IC50s: 9.7, 6.1, 12.0, 11.5, 8.6, 34.4 μM for AsPc-1, EBC-1, MKN-45, Mia-Paca-2, HT-29, K562 cells respectively).
    MET/PDGFRA-IN-2
  • HY-153831
    c-Met-IN-17
    		Inhibitor
    c-Met-IN-17 is a potent c-Met kinase inhibitor with an IC50 of 0.031 μM. c-Met-IN-17 can be used in anticancer research.. c-Met-IN-17 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    c-Met-IN-17
  • HY-P991664
    AG01
    		Inhibitor
    AG01 is a monoclonal antibody against progranulin (GP88). AG01 inhibits triple-negative breast cancer (TNBC) cell proliferation and migration, reduces the expression of phosphorylated protein kinases p-Src, p-AKT, and p-ERK, and reduces the expression of oncogenic proteins such as Axl, c-MET, HIF-1α, and VEGF. AG01 inhibits tumor growth and Ki67 expression in a TNBC xenograft mouse model. AG01 can be used in the research of TNBC and other cancers.
    AG01
  • HY-E70749
    MET D1228N Recombinant Human Active Protein Kinase
    Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET D1228N is a mutant of MET. MET D1228N Recombinant Human Active Protein Kinase is a recombinant MET D1228N protein that can be used to study MET D1228N-related functions.
    MET D1228N Recombinant Human Active Protein Kinase
  • HY-15268
    PP487
    		Inhibitor
    PP487 is a dual inhibitor of tyrosine kinase/PI(3)Ks with IC50 values of 0.017 μM, 0.072 μM, 0.004 μM, 0.01 μM, 0.55 μM, 0.22 μM, and < 0.01 μM against DNA-PK, mTOR, Hck, Src, EGFR, EphB4, and PDGFR, respectively. PP487 can be used for cancer research.
    PP487
  • HY-E70748
    MET D1228H Recombinant Human Active Protein Kinase
    Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET D1228H is a mutant of MET. MET D1228H Recombinant Human Active Protein Kinase is a recombinant MET D1228H protein that can be used to study MET D1228H-related functions.
    MET D1228H Recombinant Human Active Protein Kinase
  • HY-162868
    c-Met/HDAC-IN-4
    		Inhibitor
    c-Met/HDAC-IN-4 is a dual inhibitor of c-Met/HDAC. The IC50 value of c-Met/HDAC-IN-4 for c-Met is 28.92 nM. c-Met/HDAC-IN-4 can induce G0/G1 phase cell cycle arrest and apoptosis in MDA-MB-231 breast cancer cells, and it inhibits the proliferation and invasion of breast cancer cell lines.
    c-Met/HDAC-IN-4
  • HY-143463
    AC-386
    		Inhibitor
    AC-386 is a highly potent c-Met inhibitor with IC50 value of 7.42 nM. AC-386 has antiproliferative activities against certain cancer cell lines. AC-386 can be used for researching anti-cancer resistance.
    AC-386
  • HY-161141
    EGFR/c-Met-IN-2
    		Inhibitor
    EGFR/ C-Met-in-2 (Compound H-22) is a dual inhibitor of EGFR/c-Met. EGFR/c-Met-IN-2 inhibits cell proliferation by arresting G2/M phase. EGFR/c-Met-IN-2 has antitumor activity.
    EGFR/c-Met-IN-2
  • HY-E70755
    MET Y1230C Recombinant Human Active Protein Kinase
    Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET Y1230C is a mutant of MET. MET Y1230C Recombinant Human Active Protein Kinase is a recombinant MET Y1230C protein that can be used to study MET Y1230C-related functions.
    MET Y1230C Recombinant Human Active Protein Kinase
  • HY-170335
    PROTAC c-Met degrader-2
    		Degrader
    PROTAC c-Met degrader-2 (PROTAC2) is a PROTAC-based c-Met degrader, with a DC50 of 50 nM (Pink: Foretinib (HY-10338); Black: linker (HY-45124); Blue: CRBN ligand Thalidomide-4-O-C2-NH2 (HY-136162A)).
    PROTAC c-Met degrader-2
  • HY-E70754
    MET Y1230A Recombinant Human Active Protein Kinase
    Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET Y1230A is a mutant of MET. MET Y1230A Recombinant Human Active Protein Kinase is a recombinant MET Y1230A protein that can be used to study MET Y1230A-related functions.
    MET Y1230A Recombinant Human Active Protein Kinase
  • HY-150576
    c-Met-IN-13
    		Inhibitor
    c-Met-IN-13 is a potent c-Met inhibitor with an IC50 value of 2.43 nM. c-Met-IN-13 shows excellent cytotoxicity for cancer cells. c-Met-IN-13 shows antiproliferative activity in a concentration- and time- dependent manner. c-Met-IN-13 has the potential for the research of cancer.
    c-Met-IN-13
  • HY-147694
    c-Met-IN-11
    		Inhibitor
    c-Met-IN-11 (compound 3) is a potent c-MET and VEGFR-2 inhibitor, with IC50 values of 41.4 and 71.1 nM, respectively.
    c-Met-IN-11
  • HY-152852S
    Mefatinib-d6
    		Inhibitor
    Mefatinib-d6 free base (Mifanertinib-d6) is the deuterium labeled Mefatinib. Mefatinib is a potent tyrosine kinase inhibitor with antineoplastic activity.
    Mefatinib-d<sub>6</sub>
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity